We suggest that a combination of eIF5A2 targeted therapy and cisplatin chemotherapy is probably an effective strategy to reverse hypoxia-induced cisplatin resistance and inhibit NSCLC development. The gene discussed is EIF5A2; the disease is non-small cell lung carcinoma.